References
References 1. Keenan JM. Treatment of patients with lipid disorders in the primary care setting: New treatment guidelines and their implications. South Med J 2003; 96: 266–275.KeenanJMTreatment of patients with lipid disorders in the primary care setting: New treatment guidelines and their implicationsSouth Med J200396266 2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486–2497.Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adultsJAMA20012852486 3. Burton TM, Adams C. New government cholesterol standards would triple number of prescriptions. Wall St J, May 16, 2001.BurtonTM]]AdamsCNew government cholesterol standards would triple number of prescriptionsWall St J&NA;&NA;16May2001 4. Ewy GA. Antioxidant therapy for coronary artery disease: Don't paint the walls without treating the termites! Arch Intern Med 1999; 159: 1279–1280.EwyGAAntioxidant therapy for coronary artery disease: Don't paint the walls without treating the termitesArch Intern Med19991591279 5. GISSI-Prevenzione Investigators. Dietary supplementation with ω-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results from the GISSI-Prevenzione trial. Lancet 1999; 354: 447–455.GISSI-Prevenzione InvestigatorsDietary supplementation with ω-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results from the GISSI-Prevenzione trialLancet1999354447 6. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, et al. Fish and ω-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815–1822.HuFB]]BronnerL]]WillettWC]]StampferMJ]]RexrodeKM]]AlbertCMFish and ω-3 fatty acid intake and risk of coronary heart disease in womenJAMA20022871815 7. Kaplan RC, Frishman WH. Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 2001; 3: 326–332.KaplanRC]]FrishmanWHSystemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapyHeart Dis20013326 8. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events Investigators. Circulation 1998; 98: 839–844.RidkerPM]]RifaiN]]PfefferMA]]SacksFM]]MoyeLA]]GoldmanSInflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events InvestigatorsCirculation199898839 9. Ridker PM, Stampfer JM, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–2485.RidkerPM]]StampferJM]]RifaiNNovel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial diseaseJAMA20012852481 10. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89: 901–908.BickelC]]RupprechtHJ]]BlankenbergS]]Espiniola-KleinC]]SchlittA]]RippinGRelation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery diseaseAm J Cardiol200289901 11. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD, and the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446–1452.HeeschenC]]HammCW]]LaufsU]]SnapinnS]]BohmM]]WhiteHDand the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) InvestigatorsWithdrawal of statins increases event rates in patients with acute coronary syndromesCirculation20021051446 12. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, et al. Statin therapy, lipid levels, C-reactive protein, and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36: 1774–1780.HorneBD]]MuhlesteinJB]]CarlquistJF]]BairTL]]MadsenTE]]HartNIStatin therapy, lipid levels, C-reactive protein, and the survival of patients with angiographically severe coronary artery diseaseJ Am Coll Cardiol2000361774 13. Collins R, Peto R, Armitage J. The MRC/BHF heart protection study: Preliminary results. Int J Clin Pract 2002; 56: 53–56.CollinsR]]PetoR]]ArmitageJThe MRC/BHF heart protection study: Preliminary resultsInt J Clin Pract20025653 14. Nash RA. The biomedical ethics of alternative, complementary, and integrative medicine. Altern Ther 1999; 5: 92–95.NashRAThe biomedical ethics of alternative, complementary, and integrative medicineAltern Ther1999592 15. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205–207.FurbergCD]]PittBWithdrawal of cerivastatin from the world marketCurr Control Trials Cardiovasc Med20012205 16. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55–60.NewmanTB]]HulleySBCarcinogenicity of lipid-lowering drugsJAMA199627555 17. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000; 86: 257–262.PedersenTR]]WilhelmsenL]]FaergemanO]]StrandbergTE]]ThorgeirssonG]]TroedssonLFollow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol loweringAm J Cardiol200086257 18. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. Effects of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 1998; 32: 140–146.LewisSJ]]SacksFM]]MitchellJS]]EastC]]GlasserS]]KellSEffects of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trialJ Am Coll Cardiol199832140 19. Sinatra ST. “Care,” cancer and coenzyme Q10. J Am Coll Cardiol 1999; 33: 897–899.SinatraST“Care,” cancer and coenzyme Q10J Am Coll Cardiol199933897 20. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 1997; 234: 296–299.FolkersK]]OsterborgA]]NylanderM]]MoritaM]]MellstedtHActivities of vitamin Q10 in animal models and a serious deficiency in patients with cancerBiochem Biophys Res Commun1997234296 21. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: A case-control study. Neurology 2002; 58: 1333–1337.GaistD]]JeppesenU]]AndersenM]]Garcia RodriguezLA]]HallasJ]]SindrupSHStatins and risk of polyneuropathy: A case-control studyNeurology2002581333 22. Maron DJ, Fazio S, Linton MF. Current perspectives on statin
s. Circulation 2000; 101: 207–213.MaronDJ]]FazioS]]LintonMFCurrent perspectives on statinsCirculation2000101207 23. Oldemeyer JB, Lund RJ, Koch M, Meares AJ, Dunlay R. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology 2000; 94: 127–128.OldemeyerJB]]LundRJ]]KochM]]MearesAJ]]DunlayRRhabdomyolysis and acute renal failure after changing statin-fibrate combinationsCardiology200094127 24. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy: A case report. Angiology 2000; 51: 695–697.OzdemirO]]BoranM]]GokceV]]UzunY]]KocakB]]KorkmazSA case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy: A case reportAngiology200051695 25. Baker SK, Tranopolsky MA. Statin myopathies: Pathophysiologic and clinical perspectives. Clin Invest Med 2001; 24: 258–272.BakerSK]]TranopolskyMAStatin myopathies: Pathophysiologic and clinical perspectivesClin Invest Med200124258 26. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet 1989; 2: 1097–1098.WalravensPA]]GreeneC]]FrermanFELovastatin, isoprenes, and myopathyLancet198921097 27. Ornish D. Statins and the soul of medicine. Am J Cardiol 2002; 89: 1286–1290.OrnishDStatins and the soul of medicineAm J Cardiol2002891286 28. Pignone M, Phillips C, Mulrow C. Primary prevention of CHD with pharmacological lipid-lowering therapy: A meta-analysis of randomized trials. BMJ 2000; 321: 983–986.PignoneM]]PhillipsC]]MulrowCPrimary prevention of CHD with pharmacological lipid-lowering therapy: A meta-analysis of randomized trialsBMJ2000321983 29. Wayhs R, Zelinger A, Raggi P. High coronary calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol 2002; 39: 225–230.WayhsR]]ZelingerA]]RaggiPHigh coronary calcium scores pose an extremely elevated risk for hard eventsJ Am Coll Cardiol200239225 &NA; People in distress never think you feel enough.–Samuel Johnson (1709–1784)
